Ten Principles for Access to Multi-disease Molecular Diagnostics: A Global Call to Action
Statement / Press • 2022Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign are pleased to launch the Principles for Access to Multi-disease Molecular Diagnostics.
New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
Statement / Press • 2022We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Statement / Press • 2022Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast
Publication • 2022In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.
Let’s Talk! HIV Vaccines 101
Webinars • 2022On May 18, 2022, Treatment Action Group (TAG), the Black AIDS Institute (BAI), and the Southern AIDS Coalition (SAC) participated in this fun and informative Instagram Live discussion commemorating HIV Vaccine Awareness. Day.
World Malaria Day 2022 Long-Acting Technologies Community Advisory Board (LAT-CAB) Statement
Statement / Press • 2022As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing 12 countries, vast civil society networks, and people living with and affected by malaira, HIV, tuberculosis, and hepatitis C across the world – in reflection of World Malaria Day on April 25, 2022 – we are shocked and united in anger at the health disparities and slow progress in meeting malaria eradication goals set out in the WHO Global Technical Strategy for Malaria 2016-2030.
TAG Submission to WHO Public Hearing Regarding a New International Instrument on Pandemic Preparedness and Response
Letters • 2022At the first of these two public hearings TAG submitted the following statement with six reasons why the new international instrument must explicitly acknowledge the right to science as a central guiding framework.
2022 Pre- and Post-CROI Community HIV Cure Research Workshop
Webinars • 2022The 2022 Community HIV Cure Research Workshop took place virtually this year due to the ongoing COVID-19 pandemic. There were two sessions, the first on Tuesday February 8th and the second on Tuesday March 1st.
European Commitments to TB R&D Investments: Promises Made to Be Broken?
Publication • 2022In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
Statement from TAG’s HIV Project on FDA’s Approval of Injectable Pre-Exposure Prophylaxis
Statement / Press • 2021Treatment Action Group (TAG) welcomes and celebrates the U.S. Food and Drug Administration’s (FDA) approval of Apretude brand cabotegravir, the first injectable medication for use as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission.